首页> 外文期刊>Drugs in R&D >Efficacy and Safety of Budesonide in the Treatment of Eosinophilic Esophagitis: Updated Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies
【24h】

Efficacy and Safety of Budesonide in the Treatment of Eosinophilic Esophagitis: Updated Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies

机译:布地奈德治疗嗜酸性食管炎的有效性和安全性:随机和非随机研究的最新系统评价和荟萃分析

获取原文
       

摘要

h3 class="Heading"Background and Objective/h3p id="Par1" class="Para"Eosinophilic esophagitis (EE) is an immune/antigen-driven inflammation that causes esophageal dysfunction. Budesonide has shown promising effect in the management of EE in multiple studies, and we therefore conducted this systematic review/meta-analysis to assess budesonide efficacy and safety in order to provide more updated and robust evidence. h3 class="Heading"Methods/h3p id="Par2" class="Para"In April 2018, we conducted a systematic electronic search through four databases: PubMed, Scopus, Web of Science (ISI), and Cochrane Central. All original studies reporting the efficacy of budesonide in the treatment of EE were included in our meta-analysis. The Cochrane Collaboration tool was employed to assess the risk of bias among included randomized controlled trials, while the Newcastle–Ottawa Scale was used for non-randomized studies. h3 class="Heading"Results/h3p id="Par3" class="Para"A total of 12 studies including 555 participants were included in our review. Budesonide showed marked efficacy at the level of histological response compared to placebo [risk ratio (RR) (95% confidence interval (CI)) 11.93 (4.82–29.50); p ?0.001]. Analysis of randomized and non-randomized studies revealed considerable reduction in eosinophil count, with a mean difference (MD) (95% CI) of ??69.41 (??105.31 to ??33.51; p? 0.001) and 46.85 (33.93–59.77; p? 0.001), respectively. Similarly, there was a marked improvement in the clinical symptoms via the analysis of randomized and non-randomized studies, with an RR (95% CI) of 1.72 (1.22–2.41; p =?0.002) and MD (95% CI) of 2.45 (0.76–4.15; p =?0.005), respectively. h3 class="Heading"Conclusion/h3p id="Par4" class="Para"Budesonide showed significant effect at all treatment endpoints. However, since budesonide carries a risk of candidiasis and our inferences are based only on a small number of included studies, more research is warranted to clarify these results.
机译:class =“ Heading”>背景和目的 id =“ Par1” class =“ Para”>嗜酸性食管炎(EE)是一种免疫/抗原驱动的炎症,会引起食管功能障碍。布地奈德在多项研究中显示出对EE的治疗有希望的效果,因此,我们进行了系统的综述/元分析以评估布地奈德的疗效和安全性,以便提供更新和可靠的证据。 class =“ Heading”>方法 id =“ Par2” class =“ Para”>在2018年4月,我们通过四个数据库进行了系统的电子搜索:PubMed,Scopus,Web of Science(ISI)和Cochrane Central。所有原始报告报道布地奈德治疗EE的功效均纳入我们的荟萃分析。使用Cochrane合作工具评估了随机对照试验中偏倚的风险,而纽卡斯尔-渥太华量表则用于非随机研究。 class =“ Heading”>结果 id =“ Par3” class =“ Para”>总共12项研究(包括555名参与者)纳入了我们的评价。与安慰剂相比,布地奈德在组织学应答水平上显示出显着的疗效[风险比(RR)(95%置信区间(CI))11.93(4.82–29.50); p> 0.001]。对随机和非随机研究的分析显示,嗜酸性粒细胞计数显着降低,平均差异(MD)(95%CI)分别为?? 69.41(?? 105.31至?? 33.51; p?<0.001)和46.85(33.93– 59.77; p <0.001。同样,通过随机和非随机研究的分析,临床症状也有明显改善,RR(95%CI)为1.72(1.22-2.41; p =?0.002),MD(95%CI)为1.72(1.22–2.41; p =?0.002)。分别为2.45(0.76-4.15; p =?0.005)。 class =“ Heading”>结论 id =“ Par4” class =“ Para”>布地奈德在所有治疗终点均显示出显着效果。但是,由于布地奈德具有念珠菌病的风险,并且我们的推论仅基于少数纳入研究,因此有必要进行更多研究以阐明这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号